Ultimately, overcoming these challenges would enable NAT2 methylation analysis to complement existing clinical biomarkers and genetic tests, offering a valuable tool for the early detection and personalized management of ATDILI risk in tuberculosis patients. This evidence concerns the gene NAT2 and tuberculosis.